Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Riyazuddin M. Shaik"'
Autor:
Hiam Chemaitelly, Patrick Tang, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Mohammad R. Hasan, Houssein H. Ayoub, Heba N. Altarawneh, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed G. Al-Kuwari, Adeel A. Butt, Hamad E. Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J. Abu-Raddad
Publikováno v:
New England Journal of Medicine. 388:665-667
Autor:
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, Jeremy Samuel Faust, Patrick Tang, Peter Coyle, HADI M. YASSINE, Asmaa Althani, Hebah A. Al-Khatib, Mohammad R. Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath Nasrallah, Mohamed G. Al-Kuwari, Adeel A Butt, Hamad Eid Al-Romaihi, Mohammed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J Abu-Raddad
Qatar introduced COVID-19 bivalent vaccination for persons ≥12 years old using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains. We estimated effectiveness of this bivalent vaccine against SARS-CoV-2 infectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f729d32d8794226ff980e45d2de191a0
https://doi.org/10.1101/2023.04.15.23288612
https://doi.org/10.1101/2023.04.15.23288612
Autor:
Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Mohammad R. Hasan, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed G. Al-Kuwari, Adeel A. Butt, Hamad E. Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J. Abu-Raddad
Publikováno v:
New England Journal of Medicine. 387:1716-1718
Autor:
Laith J. Abu-Raddad, Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Patrick Tang, Mohammad R. Hasan, Peter Coyle, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al-Kuwari, Adeel A. Butt, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini
Publikováno v:
Abu-Raddad, L J, Chemaitelly, H, Ayoub, H H, AlMukdad, S, Yassine, H M, Al-Khatib, H A, Smatti, M K, Tang, P, Hasan, M R, Coyle, P, Al-Kanaani, Z, Al-Kuwari, E, Jeremijenko, A, Kaleeckal, A H, Latif, A N, Shaik, R M, Abdul-Rahim, H F, Nasrallah, G K, Al-Kuwari, M G, Butt, A A, Al-Romaihi, H E, Al-Thani, M H, Al-Khal, A & Bertollini, R 2022, ' Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar ', New England Journal of Medicine . https://doi.org/10.1056/NEJMoa2200797
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited efforts to scale up booster vac
Autor:
Hiam Chemaitelly, Patrick Tang, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Mohammad R. Hasan, Houssein H. Ayoub, Heba N. Altarawneh, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed G. Al-Kuwari, Adeel A. Butt, Hamad E. Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J. Abu-Raddad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b2517923bb50ef7fc557b2bbed8c18d
https://doi.org/10.1101/2022.10.29.22281606
https://doi.org/10.1101/2022.10.29.22281606
Autor:
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, Mohammad R. Hasan, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed G. Al-Kuwari, Adeel A. Butt, Hamad E. Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Patrick Tang, Laith J. Abu-Raddad
Publikováno v:
The New England journal of medicine. 387(17)
Autor:
Heba N. Altarawneh, Hiam Chemaitelly, Mohammad R. Hasan, Houssein H. Ayoub, Suelen Qassim, Sawsan AlMukdad, Peter Coyle, Hadi M. Yassine, Hebah A. Al-Khatib, Fatiha M. Benslimane, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed G. Al-Kuwari, Adeel A. Butt, Hamad E. Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Patrick Tang, Laith J. Abu-Raddad
Publikováno v:
New England Journal of Medicine. 386:1288-1290
Autor:
Adeel A, Butt, Soha R, Dargham, Patrick, Tang, Hiam, Chemaitelly, Mohammad R, Hasan, Peter V, Coyle, Anvar H, Kaleeckal, Ali Nizar, Latif, Srusvin, Loka, Riyazuddin M, Shaik, Ahmed, Zaqout, Muna A, Almaslamani, Abdullatif, Al Khal, Roberto, Bertollini, Abdul-Badi, Abou-Samra, Laith J, Abu-Raddad
Publikováno v:
Journal of Global Health. 12
Understanding the disease severity associated with the Omicron variant of the SARS-CoV-2 virus is important in determining appropriate management strategies at the individual and population levels. We determined the severity of SARS-CoV-2 infection i
Autor:
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Hebah A. Al-Khatib, Maria K. Smatti, Peter Coyle, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar H. Kaleeckal, Ali N. Latif, Riyazuddin M. Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed G. Al-Kuwari, Adeel A. Butt, Hamad E. Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J. Abu-Raddad
Publikováno v:
The New England journal of medicine. 387(1)
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) variant is unclear. We conduct